On this page

Permethrin

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Permethrin
Generic name
Permethrin
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
10
Packages
10
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Permethrin 50 mg/100g 106387 —
Permethrin 50 mg/g 106387 —

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
20

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Pyrethrins [CS] CS 1 member — no class page
Pyrethroid [EPC] EPC 1 member — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
211303
Application type
ANDA · Abbreviated New Drug Application
Approval date
April 3, 2019
Sponsor
ENCUBE ETHICALS
Products on application
1
Submissions recorded
1
Products approved under application 211303.
Product Trade name Form Strength Ingredient Status TE Flags
211303-001 PERMETHRIN CREAM PERMETHRIN Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 211303.
Type No. Action Status Date Review
Original application 1 Approved April 3, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260813). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260813 HUMAN PRESCRIPTION DRUG · 20260724 HUMAN PRESCRIPTION DRUG · 20260304 HUMAN PRESCRIPTION DRUG · 20251009

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Permethrin Cream 5% w/w is indicated for the treatment of infestation with Sarcoptesscabiei (scabies).

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Adults and children - Thoroughly massage Permethrin Cream 5% w/w into the skin from the head to the soles of the feet. Scabies rarely infests the scalp of adults, although the hairline, neck, temple, and forehead may be infested in infants and geriatric patients. Usually 30 grams is sufficient for an average adult. The cream should be removed by washing (shower or bath) after 8 to 14 hours. Infants should be treated on the scalp, temple, and forehead. ONE APPLICATION IS GENERALLY CURATIVE . Patients may experience persistent pruritus after treatment. This is rarely a sign of treatment failure and is not an indication for retreatment. Demonstrable living mites after 14 days indicate that retreatment is necessary.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Permethrin Cream 5% w/w is contraindicated in patients with known hypersensitivity to any of its components, to any synthetic pyrethroid or pyrethrin.

WARNINGS If hypersensitivity to Permethrin Cream 5% w/w occurs, discontinue use.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In clinical trials, generally mild and transient burning and stinging followed application with permethrin cream 5% in 10% of patients and was associated with the severity of infestation. Pruritus was reported in 7% of patients at various times post-application. Erythema, numbness, tingling, and rash were reported in 1 to 2% or less of patients (see PRECAUTIONS-General ). Other adverse events reported since marketing permethrin cream 5% include: headache, fever, dizziness, abdominal pain, diarrhea and nausea and/or vomiting. Although extremely uncommon and not expected when used as directed (see DOSAGE AND ADMINISTRATION ), rare occurrences of seizure have been reported. None have been medically confirmed as associated with permethrin cream 5% treatment. To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Permethrin Cream, 5% is a topical scabicidal agent for the treatment of infestation with Sarcoptes scabiei (scabies). It is available in an off-white, greaseless, uniform mass. Permethrin Cream, 5% is for topical use only. Chemical Name - The permethrin used is an approximate 1:3 mixture of the cis and trans isomers of the pyrethroid 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid, (3-phenoxyphenyl) methyl ester. Permethrin has a molecular formula of C 21 H 20 CI 2 O 3 and a molecular weight of 391.29. It is a colorless or slightly brownish viscous liquid, semi-solid or crystalline solid. Active Ingredient - Each gram contains permethrin 50 mg (5%). Inactive Ingredients - Butylated hydroxytoluene, carbomer homopolymer type B, ceteth-2, ceteth-20, glycerin, isopropyl myristate, lanolin alcohols, medium chain triglycerides, mineral oil, mono and di-glycerides, purified water, and sodium hydroxide. Formaldehyde 1 mg (0.1%) is added as a preservative. Chemical Structure

OVERDOSAGE No instance of accidental ingestion of Permethrin Cream 5% w/w has been reported. If ingested, gastric lavage and general supportive measures should be employed. Excessive topical use (see DOSAGE AND ADMINISTRATION ) may result in increased irritation and erythema.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Permethrin Cream 5% w/w is available as follows: 60 g tube 68788-8439-6 STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa – 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713 USA Rev 04 May 2025 Relabeled By: Preferred Pharmaceuticals Inc.

Adverse event reports

Source: openFDA FAERS
1,746
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: PERMETHRIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-5888-0 50090-5888 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-5888-0) / 60 g in 1 TUBE December 30, 2021
84386-073-60 84386-073 Aurobindo Pharma Limited 1 TUBE in 1 CARTON (84386-073-60) / 60 g in 1 TUBE January 22, 2024
71335-2899-1 71335-2899 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2899-1) / 60 g in 1 TUBE October 24, 2025
72162-2171-6 72162-2171 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2171-6) / 60 g in 1 TUBE December 7, 2023
43598-481-60 43598-481 Dr. Reddy's Laboratories, Inc. 1 TUBE in 1 CARTON (43598-481-60) / 60 g in 1 TUBE August 26, 2026
21922-021-07 21922-021 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-021-07) / 60 g in 1 TUBE April 8, 2019
16714-897-01 16714-897 Northstar Rx LLC 1 TUBE in 1 CONTAINER (16714-897-01) / 60 g in 1 TUBE April 8, 2019
45802-269-37 45802-269 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-269-37) / 60 g in 1 TUBE August 11, 2006
68788-8439-6 68788-8439 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8439-6) / 60 g in 1 TUBE June 5, 2023
70518-2945-0 70518-2945 REMEDYREPACK INC. 1 TUBE in 1 CARTON (70518-2945-0) / 60 g in 1 TUBE April 8, 2019
50090-5888 50090-5888 A-S Medication Solutions — April 8, 2019
84386-073 84386-073 Aurobindo Pharma Limited — January 22, 2024
71335-2899 71335-2899 Bryant Ranch Prepack — August 11, 2006
72162-2171 72162-2171 Bryant Ranch Prepack — August 11, 2006
43598-481 43598-481 Dr. Reddy's Laboratories, Inc. — August 26, 2026
21922-021 21922-021 Encube Ethicals, Inc. — April 8, 2019
16714-897 16714-897 Northstar Rx LLC — April 8, 2019
45802-269 45802-269 Padagis Israel Pharmaceuticals Ltd — August 11, 2006
68788-8439 68788-8439 Preferred Pharmaceuticals Inc. — June 5, 2023
70518-2945 70518-2945 REMEDYREPACK INC. — April 8, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.